Introduction
This policy fully supports the recommendations for clinical practice & training in transfusion medicine published by the National Institute of Health & Care Excellence (NICE), British Society for Haematology (BSH), the National Blood Transfusion Committee (NBTC), the Serious Hazards of Transfusion (SHOT) scheme & other national / local guidelines as referenced. This policy encompasses all blood components / products & has appendices covering guidance on specific issues as listed in the contents page
Ashford & St Peters NHS Foundation Trust is committed to the provision of a service that is fair, accessible and meets the needs of all individuals.
Scope of the Policy
All staff involved in sampling, prescribing, ordering, collecting, administration of blood components / products & care/monitoring of a patient receiving a transfusion must read the sections relevant to their place of work & role.
This policy applies to adult patients at Ashford & St Peters NHS Foundation Trust and the satellite hospitals that use blood components/products supplied by the Transfusion Laboratories.
Appendices
- Appendix A: Indication for Blood Components
- Appendix B: Specific Requirements
- Appendix C: Blood Collection procedures
- Appendix D: Acute Transfusion Reaction Management
- Appendix E: Anti-D prophylaxis, Fetal RhD testing, & management of maternal antibodies
- Appendix F: Massive Haemorrhage Management
- Appendix G: Surgical Transfusion
- Appendix H: Tranexamic acid
- Appendix I: Safe Transfusion in haemopoietic stem cell transplant patients
- Appendix J: Abbreviations
Policy Details
Download: | PDF version |
Compiled by: | Kim East, Lead Transfusion Practitioner Matthew Rogers, BSPS Lead for Transfusion Consultant Haematologist |
Ratified by: | ASPH Patient Blood Management Committee BSPS Joint Patient Blood Management Team Quality and Safety Committee |
Date Ratified: | August 2022 |
Date Issued: | August 2022 |
Review Date: | February 2023 |
Target Audience: | All staff involved with blood transfusion and any associated blood products including anti-D and Beriplex. |
Contact name: | Kim East, Matthew Rogers |